Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22972

1.

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.

Varkaris A, Katsiampoura A, Davis JS, Shah N, Lam M, Frias RL, Ivan C, Shimizu M, Morris J, Menter D, Overman M, Tran H, Heymach J, Chun YS, Vauthey JN, Calin G, Kopetz S.

Br J Cancer. 2019 Jan 14. doi: 10.1038/s41416-018-0360-y. [Epub ahead of print]

PMID:
30636774
2.

Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours.

Rizzo FM, Vesely C, Childs A, Marafioti T, Khan MS, Mandair D, Cives M, Ensell L, Lowe H, Akarca AU, Luong T, Caplin M, Toumpanakis C, Krell D, Thirlwell C, Silvestris F, Hartley JA, Meyer T.

Br J Cancer. 2019 Jan 14. doi: 10.1038/s41416-018-0367-4. [Epub ahead of print]

PMID:
30636773
3.

Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.

Liu C, He H, Li X, Su MA, Cao Y.

Br J Cancer. 2018 Dec 27. doi: 10.1038/s41416-018-0363-8. [Epub ahead of print]

PMID:
30587849
4.

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.

Páez D, Tobeña M, Fernández-Plana J, Sebio A, Virgili AC, Cirera L, Barnadas A, Riera P, Sullivan I, Salazar J.

Br J Cancer. 2018 Dec 26. doi: 10.1038/s41416-018-0348-7. [Epub ahead of print]

PMID:
30585257
5.

Personal radio use and cancer risks among 48,518 British police officers and staff from the Airwave Health Monitoring Study.

Gao H, Aresu M, Vergnaud AC, McRobie D, Spear J, Heard A, Kongsgård HW, Singh D, Muller DC, Elliott P.

Br J Cancer. 2018 Dec 26. doi: 10.1038/s41416-018-0365-6. [Epub ahead of print]

PMID:
30585256
6.

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.

de Weger VA, de Jonge M, Langenberg MHG, Schellens JHM, Lolkema M, Varga A, Demers B, Thomas K, Hsu K, Tuffal G, Goodstal S, Macé S, Deutsch E.

Br J Cancer. 2018 Dec 26. doi: 10.1038/s41416-018-0355-8. [Epub ahead of print]

PMID:
30585255
7.

Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.

Li Z, Liao J, Yang Z, Choi EY, Lapidus RG, Liu X, Cullen KJ, Dan H.

Br J Cancer. 2018 Dec 26. doi: 10.1038/s41416-018-0351-z. [Epub ahead of print]

PMID:
30585254
8.

Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".

Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ.

Br J Cancer. 2018 Dec 25. doi: 10.1038/s41416-018-0344-y. [Epub ahead of print] No abstract available.

PMID:
30584261
9.

Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105000 UK women in the Generations Study'.

Kyba CCM, Spitschan M.

Br J Cancer. 2018 Dec 25. doi: 10.1038/s41416-018-0203-x. [Epub ahead of print] No abstract available.

PMID:
30584260
10.

Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.

Conway AM, Mitchell C, Kilgour E, Brady G, Dive C, Cook N.

Br J Cancer. 2018 Dec 23. doi: 10.1038/s41416-018-0332-2. [Epub ahead of print] Review.

PMID:
30580378
11.

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.

Pegram MD, Bondarenko I, Zorzetto MMC, Hingmire S, Iwase H, Krivorotko PV, Lee KS, Li RK, Pikiel J, Aggarwal R, Ewesuedo R, Freyman A, Li R, Vana A, Yin D, Zacharchuk C, Tan-Chiu E.

Br J Cancer. 2018 Dec 20. doi: 10.1038/s41416-018-0340-2. [Epub ahead of print]

PMID:
30568294
12.

Long-term risk of screen-detected and interval breast cancer after false-positive results at mammography screening: joint analysis of three national cohorts.

Román M, Hofvind S, von Euler-Chelpin M, Castells X.

Br J Cancer. 2018 Dec 19. doi: 10.1038/s41416-018-0358-5. [Epub ahead of print]

PMID:
30563993
13.

Whole-colon investigation vs. flexible sigmoidoscopy for suspected colorectal cancer based on presenting symptoms and signs: a multicentre cohort study.

Cross AJ, Wooldrage K, Robbins EC, Pack K, Brown JP, Hamilton W, Thompson MR, Flashman KG, Halligan S, Thomas-Gibson S, Vance M, Saunders BP, Atkin W.

Br J Cancer. 2018 Dec 19. doi: 10.1038/s41416-018-0335-z. [Epub ahead of print]

PMID:
30563992
14.

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.

Lopez-Knowles E, Pearson A, Schuster G, Gellert P, Ribas R, Yeo B, Cutts R, Buus R, Garcia-Murillas I, Haynes B, Martin LA, Smith I, Turner N, Dowsett M.

Br J Cancer. 2018 Dec 19. doi: 10.1038/s41416-018-0345-x. [Epub ahead of print]

PMID:
30563991
15.

Alterations in serum amino-acid profile in the progression of colorectal cancer: associations with systemic inflammation, tumour stage and patient survival.

Sirniö P, Väyrynen JP, Klintrup K, Mäkelä J, Karhu T, Herzig KH, Minkkinen I, Mäkinen MJ, Karttunen TJ, Tuomisto A.

Br J Cancer. 2018 Dec 19. doi: 10.1038/s41416-018-0357-6. [Epub ahead of print]

PMID:
30563990
16.

Kidney stones and the risk of renal cell carcinoma and upper tract urothelial carcinoma: the Netherlands Cohort Study.

van de Pol JAA, van den Brandt PA, Schouten LJ.

Br J Cancer. 2018 Dec 19. doi: 10.1038/s41416-018-0356-7. [Epub ahead of print]

PMID:
30563989
17.

Oncofoetal insulin receptor isoform A marks the tumour endothelium; an underestimated pathway during tumour angiogenesis and angiostatic treatment.

Nowak-Sliwinska P, van Beijnum JR, Huijbers EJM, Gasull PC, Mans L, Bex A, Griffioen AW.

Br J Cancer. 2018 Dec 18. doi: 10.1038/s41416-018-0347-8. [Epub ahead of print]

PMID:
30559346
18.

(Pro)renin receptor promotes colorectal cancer through the Wnt/beta-catenin signalling pathway despite constitutive pathway component mutations.

Wang J, Shibayama Y, Zhang A, Ohsaki H, Asano E, Suzuki Y, Kushida Y, Kobara H, Masaki T, Wang Z, Nishiyama A.

Br J Cancer. 2018 Dec 17. doi: 10.1038/s41416-018-0350-0. [Epub ahead of print]

PMID:
30555158
19.

Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma.

Ma H, Yang W, Zhang L, Liu S, Zhao M, Zhou G, Wang L, Jin S, Zhang Z, Hu J.

Br J Cancer. 2018 Dec 17. doi: 10.1038/s41416-018-0352-y. [Epub ahead of print]

PMID:
30555157
20.

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.

Nardone A, Weir H, Delpuech O, Brown H, De Angelis C, Cataldo ML, Fu X, Shea MJ, Mitchell T, Veeraraghavan J, Nagi C, Pilling M, Rimawi MF, Trivedi M, Hilsenbeck SG, Chamness GC, Jeselsohn R, Osborne CK, Schiff R.

Br J Cancer. 2018 Dec 17. doi: 10.1038/s41416-018-0354-9. [Epub ahead of print]

PMID:
30555156

Supplemental Content

Loading ...
Support Center